Characteristic | Posaconazole administration | |
---|---|---|
2 x per day (n = 6) | 3 x per day (n = 8) | |
No. of patients (%) | ||
Gender | ||
Male | 2 (33.3) | 5 (62.5) |
Female | 4 (66.6) | 3 (37.5) |
Age group | ||
< 6 years | 3 (5.0) | 6 (75.0) |
6-11 years | 3 (5.0) | 2 (25.0) |
Donor | ||
MUD | 2 (33.3) | 3 (37.5) |
MMFD | 2 (33.3) | 5 (62.2) |
MFD | 2 (33.3) | 0 (0) |
Primary diagnosis | ||
ALL | 1 (16.7) | 2 (25.0) |
Biphenotypic leukemia | 0 (0) | 1 (12.5) |
Solid tumors | 1 (16.7) | 0 (0) |
Aplastic anemia | 2 (33.3) | 1 (12.5) |
Neurometabolic diseases | 1 (16.7) | 1 (12.5) |
Immunodeficiency | 1 (16.7) | 3 (37.5) |
Graft-versus-Host disease | ||
Grade I | 2 (33.3) | 2 (25.0) |
Grade II | 0 (0) | 2 (25.0) |
Grade III | 0 (0) | 0 (0) |
Grade IV | 0 (0) | 0 (0) |
Chronic limited | 0 (0) | 0 (0) |
Chronic extensive | 0 (0) | 0 (0) |